Objective-Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking.
A rterial thrombus formation is initiated by flow-dependent interactions of blood platelets and plasma components with the damaged vessel wall. In the past few decades, microfluidic devices, which are more commonly called flow chambers, have been increasingly used to model the pathophysiology of thrombus formation (for review see 1 ). By modulating parameters, such as the coating surface (eg, collagen±tissue factor [TF] , atheromatous plaque material, VWF [von Willebrand Factor]), the shear stress applied (eg, venous versus arterial flow, laminar versus turbulent flow), the type of blood cell perfusate (eg, platelet-rich plasma, washed platelets, or anticoagulated whole blood), various microfluidic models have been developed and have helped to determine the mechanisms of thrombus formation in different pathophysiological conditions. 2, 3 The good correlation between results from flow chamber experiments and those of in vivo studies of thrombus formation in mice has shown that many mechanistic aspects of arterial thrombosis can be analyzed using microfluidic flow devices, with the advantage of allowing the use of human blood cells and drugs for clinical use.
Microfluidic devices have provided important insights into the mechanisms that regulate platelet adhesion and activation under flow, as well as on the role of the coagulation system in this setting. For instance, flow chamber studies have been useful to decipher the respective roles of the GP (glycoprotein) Ib-VWF axis, GPVI, and integrin α2β1 in platelet adhesion and activation on collagen at different shear stresses. 4, 5 By allowing the measurement of fibrin deposition and platelet aggregate size in blood from hemophilic patients, flow chamber experiments have shown that platelet aggregate size, but not fibrin deposition, could discriminate between severe and moderate FVIII (factor VIII) deficiencies. 6, 7 Flow chamber experiments have also been used to evaluate von Willebrand disease and may be useful to characterize abnormalities in VWF binding to collagen at physiological and pathological shear stresses. [8] [9] [10] In addition to recapitulating some features of thrombosis, 11 microfluidic assays also have the potential to guide the dosage of antiplatelet agents and to evaluate novel antiplatelet treatments. For example, microfluidic assays are sensitive to COX-1 (cyclooxygenase 1), P2Y (purinoreceptor) 1, and P2Y12 inhibitors and can detect differences in inter-individual sensitivity to aspirin or inhibitors of the ADP receptors.
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The fibrinolytic system is responsible for the proteolytic degradation of fibrin clots and is currently considered to be a major player in the size, stability, and resorption of a thrombus. Several methods are used to study fibrinolysis but none are fully representative of what happens in vivo because they are performed either in the absence of blood cells (clot lysis assays and microscopic lysis velocity) or in static conditions (thromboelastometry). Nevertheless, microfluidic technology has been used to mimic trauma-induced coagulopathy in a recent study. In this model, tPA (tissue-type plasminogen activator) was added to the blood to model the effect of hyperfibrinolysis on clot formation and stability. 15 Importantly, thrombolysis by intravenous r-tPA (recombinant tPA) is the only approved medical treatment for patients with acute ischemic stroke. 16 However, the therapeutic use of r-tPA has 2 major drawbacks: limited efficacy and a risk of bleeding. 17 Failure of thrombolysis may be due, among other causes, to early thrombosis recurrence, which could justify the use of r-tPA in combination with antithrombotics or antiplatelet agents but with the risk of increasing bleeding complications. 18, 19 The use and adaptation of microfluidic models for the study of thrombolysis could help to determine the mechanisms of thrombolysis resistance and thus to optimize thrombolytic therapies. The aim of the present study was to develop a microfluidic assay for the study of thrombolysis in human whole blood. Here, we describe a system suitable for comparative evaluation of thrombolytic therapeutic strategies. Interestingly, using this system, we show that platelets continue incorporating into thrombi undergoing r-tPA-mediated fibrinolysis, thus resulting in the replacement of a fibrin-rich clot by a platelet-rich thrombus.
Materials and Methods
The authors declare that all supporting data are available within the article.
Horm collagen (type I) was purchased from Nycomed Pharma (Munich, Germany). 3,3′-dihexyloxacarbocyanine iodide, Alexa Fluor (AF)-647-and AF-488-conjugated fibrinogen, and AF-594 anti-mouse IgG were from Invitrogen (Life Technologies). Lipidated recombinant TF (rTF, Innovin) was purchased from Dade Behring (Marburg, Germany). Recombinant plasminogen activator (r-tPA), alteplase was from Boehringer-Ingelheim and fluorescein isothiocyanate (FITC)-labeled tPA from Abcam, rhodamine 6G, and bovine serum albumin from Sigma (ST Quentin Fallavier, France). An antifibrin specific AF-labeled monoclonal antibody (clone 59D8) was a gift from Dr Gary Ferrell 20 and the fragment antibody (antigenbinding fragment [Fab] ) 9O12 has been extensively characterized for its inhibitory properties on GPVI functions.
21 PE (phycoerythrin)-labeled anti-human CD142 from BD Biosciences, paraformaldehyde from Electron Microscopy Sciences. Abciximab (Reopro) was from Eli Lilly (Indianapolis, IN); recombinant hirudin was from Transgene (Illkirch-Graffenstaden, France); ticagrelor was from AstraZeneca; and unfractioned heparin was from Choay. The thrombin and factor Xa fluorogenic substrate (Z-Gly-Gly-Arg-AMC) were from Diagnostica stago (Asnieres France) and human Glu-Plasminogen (ThermoScientific, France). HemoD-dimer assay was performed on ACL TOP from Instrumentation Laboratory. Please see the Major Resources Table in the online-only Data Supplement.
Ethics Statement
All blood donors (male and female) were healthy volunteers who were not under medication and gave their free and informed written consent to this research study, which conforms to the ethical standards of the Declaration of Helsinki. Legal and ethical authorization for research use of collected blood was obtained through a national convention between the French National Institute of Health and Medical Research (Inserm) and the French Blood Institute (EFS [Etablissement Francais du Sang]; convention number I/DAJ/C2675).
Whole Blood Collection and Preparation of Platelet-Free Plasma
Venous blood was collected from healthy volunteers not currently taking any medication into Vacuette (Greiner Bio-one, France) containing buffered sodium citrate (0.129 mol/L, ratio blood/sodium citrate 9:1). Whole blood was centrifuged at 2500g for 15 minutes at room temperature to prepare platelet-poor plasma and centrifuged again at 15 000g for 5 min to obtain platelet-free plasma.
Platelet Aggregation
Platelet-rich plasma (3×10 8 platelets/mL) was incubated with varying concentrations of antiplatelet drugs (Fab 9O12, ticagrelor, or abciximab) for 10 minutes at 37°C before triggering platelet aggregation with collagen (1 µg/mL) or ADP (10 µmol/L). Light transmission was continuously recorded on an APACT 4004 aggregometer (Elitech France). The concentrations of Fab9O12 (50 µg/mL) and ticagrelor (50 µmol/L) abciximab (3 µg/mL) that fully inhibited platelet aggregation were used in flow experiments.
Thrombin Generation Assay
Thrombin generation was measured in freshly prepared plateletrich plasma ( ). The first step was to produce fibrin-rich clots inside the channel: citrated blood was preincubated for 5 minutes with 3,3′-dihexyloxacarbocyanine iodide (10 μmol/L) and AF-647-conjugated fibrinogen (100 μg/mL). In some cases, blood was supplemented with the thrombin/Xa-specific fluorogenic substrate (1/125 v/v) or Alexa 647-labeled anti-fibrin antibody (24 µg/mL; 59D8). Citrated blood was mixed with CaCl 2 (10 mmol/L) at the initiation of the perfusion at arterial 150/s and venous 400/s wall shear rates. Images were acquired every second allowing one to monitor thrombus formation (platelet and fibrin(ogen) accumulation). A 3 to 4 minutes blood perfusion followed by a 1-minute wash was selected to generate, in the chosen procoagulant conditions, the formation of nonocclusive stable thrombi at 1500/s or 400/s, respectively. An average of 30 images per channel was acquired to provide an overview of thrombi formation. Thrombi grossly homogeneous in size and fibrin/platelet content were selected to image, independently of their location in the channel.
In the second step, citrated blood from the same donor was preincubated with rhodamine 6G (131 µmol/L) to differentiate new platelets from those accumulated in the thrombus during the first flow. Additionally, the blood was supplemented or not with alteplase to trigger fibrinolysis. The perfusion was for 10 minutes at initial wall shear rates of 1500/s or 400/s. Real-time changes in the fluorescence of the fibrin(ogen)-rich network, and of platelets, distinguishing between those from the first step and those newly recruited in the second step, were measured allowing quantification of both fibrinolysis and platelet behavior. Variations in the blood flow were controlled as above. At the end of the perfusion, an overview of the channels (30 images) was also acquired. When indicated, Z-stack acquisitions were immediately performed, or channels were fixed with 4% paraformaldehyde for 20 minutes at room temperature and analyzed later.
Instruments and Features
The platelet/fibrin-rich thrombi (FRT) formation, clot growth and fibrinolysis were analyzed using a Zeiss Axio Observer Z1 microscope with EC Plan-Neofluar 20×/0.5 Ph2 M27 objective equipped with an ORCA-R2 C10600 digital CCD camera (Hamamatsu) controlled by Zen2012 image capture software. A maximum of 4 channels of acquisition was recorded simultaneously with the following parameters: channel 1 for the 3,3′-dihexyloxacarbocyanine iodide (green fluorescent) platelets with reflector 38HE with wavelength excitation: 488; emission: 509; and an exposure time of 77 ms; channel 2 for differential interference contrast Trans light, exposure time: 10 ms; channel 3: for A647 fibrin(ogen) detection with reflector 50 cyanine with wavelength excitation: 650; emission: 673; and exposure time: 150 ms; and channel 4: for rhodamine-labeled (red fluorescent) platelets with reflector 43HE DsRed (Red fluorescent protein) with wavelength excitation: 545; emission: 572; and exposure time: 77 ms. The film recorded during the first step (4 minutes) was composed of 49 frames (237.95 s) while the second (10 minutes) included 108 frames (603.41 s) with a scaling per pixel of 0.645×0.645 µm and a corresponding image size of 672×512 pixels. Changes in platelets accumulation during the first and second flow steps, as well as fibrinolysis, were quantified using fluorescence intensity of the fibrin-rich clot and transformed in a corresponding percentage function of time. Z-stack acquisition and analysis of thrombi were obtained with the use of apotome (Zen2012, Zeiss) and the 3-dimensional images visualization and analysis with Imaris software. Confocal analyses were performed at the CRI U1149 Imaging facility.
Statistical Analysis
All values are presented as means±SEM. One-way or 2-way ANOVAs were used to compare means between multiple groups. After 1-or 2-way ANOVAs, Bonferroni multiple comparison tests were performed. When data failed the test for normality (ShapiroWilk, Prism), the nonparametric Mann-Whitney U test was performed. Statistical analyses were performed using Prism software (GraphPad). Differences were considered significant when P values were ≤0.05.
Results

Production of Platelet-Fibrin Thrombi Under Arterial Flow Conditions for the Study of Fibrinolysis
To study fibrinolysis under flow conditions, we used a 2-step approach in which recalcified whole blood was first perfused through TF/collagen-coated chambers (Figure 1 ). Two TF coating concentrations were compared for obtaining reproducible nonocclusive platelet/fibrin-rich clots, with balanced amounts of platelets and fibrin, in 4 minutes of perfusion. Perfusion of whole blood at 1500/s over surfaces coated with collagen (0.5 µg) and TF at 120 pmol/L led to the formation of thrombi composed of a higher proportion of platelets as compared with fibrin(ogen) (67±7% versus 33±6% mean total thrombus surface area, respectively; Figure IA and IB in the online-only Data Supplement). Perfusion of whole blood through channels coated with collagen and TF at 600 pmol/L resulted in thrombi with balanced contents of platelets and fibrin(ogen) (52±11% versus 48±12% mean total thrombus surface area, respectively; Figure IA and IB in the online-only Data Supplement). Thus, the latter mixture of collagen at 0.5 µg and TF at 600 pmol/L was chosen as the channel coating surface for the rest of the study. In those experimental settings, Factor Xa and thrombin formation, detected by a fluorogenic substrate, started as early as 15 seconds after perfusion initiation (Figure 2A ). Platelets rapidly formed aggregates as indicated by the accumulation 3,3′-dihexyloxacarbocyanine iodide-labeled platelets. Accumulation of fibrinogen-associated fluorescence was visible within 1 minute after beginning perfusion. Fibrin(ogen) deposits took the form of both large diffuse areas and more punctiform spots. Large fibrin(ogen)-rich areas were colocalized with large platelet aggregates, whereas more patchy signals were colocalized with small platelet aggregates ( Figure 2A and Movie I in the online-only Data Supplement). To ensure that the bright fibrin(ogen) thrombus staining was specific to fibrin formation, blood was supplemented with Alexa 488-labeled fibrinogen and a fibrin-specific antibody ( Figure 2B ) allowing the simultaneous recording of fibrinogen accumulation and fibrin formation. Fibrin was formed from 1 minute after the beginning of flow and accumulated mostly in the center of the fibrinogen-rich areas. This indicated that fibrin formation occurred in large thrombi, whereas in smaller aggregates, fibrinogen is rather engaged in bridging platelets. Confocal analysis showed that the base of the thrombi contained both platelets and fibrin(ogen) while the proportion of platelets increased progressively in more apical section ( Figure 2C ).
r-tPA-Induced Fibrinolysis Under Flow Positively Correlates With D-Dimer Formation
After the initial perfusion that allowed the formation of platelet/fibrin-rich clots at 1500/s or 400/s, a second perfusion using autologous blood was then performed to determine whether those clots were suitable for the study of thrombolysis in flowing whole blood conditions. Before this perfusion, blood samples were supplemented with FITC-coupled tPA and Alexa 594-conjugated plasminogen. FITC-coupled tPA bound to the large fibrin-rich clots after 2 minutes of blood perfusion ( Figure 3A and 3B) . Perfusion of PPACK (D-phenylalanylprolyl-arginyl chloromethyl ketone)-anticoagulated blood on the TF and collagen-coated surface resulted in the formation of fibrin-poor clots and in a reduced binding of FITC-coupled tPA ( Figure 3A and 3B) . Residual binding of FITC-coupled tPA was found associated with platelet aggregates. Consistent with these results, D-dimer concentration was significantly higher in the outlet of chambers containing fibrin-rich clots compared with fibrin-poor clots (4100±1162 versus 123±69 ng/mL; P<0.05 respectively; Figure 3C ). Similarly, Alexa-labeled 594 plasminogen mainly accumulated into large FRT ( Figure 3D ). To further analyze fibrinolysis in arterial and venous flow conditions, blood was supplemented with actilyse (alteplase, r-tPA), which remains the only approved pharmacological treatment option for patients with acute ischemic stroke (Figure 4A and 4B; Movies II and III in the online-only Data Supplement). Fibrinolysis was achieved in 10 minutes with 15 µg/mL r-tPA and was significantly higher at venous wall shear rate (400/s) compared with arterial wall shear rate (1500/s) with a rate of 67±5.4% versus 45±3.4% (P<0.001, n=34 and n=6, respectively; Figure 4A and 4B). Lower concentrations of r-tPA were less efficient to induce reproducible fibrinolysis in this given time lapse of 10 minutes at 1500/s (data not shown). Fibrinolysis underflow was also assessed by measurement of D-dimers at the outlet of the chamber. In the absence of r-tPA, the concentration of D-dimers at 1500/s and 400/s was similar to that measured in platelet-poor plasma (208±26 and 226±59 versus 258±17 ng/ mL, respectively). In contrast, the addition of 15 µg/mL r-tPA resulted in an increase in D-dimer levels in the blood collected at the outlet of the chamber at 1500/s and 400/s (3900±775 and 9895±1569 ng/mL; P=0.0001, n>7, respectively; Figure 4C ), thus confirming the induction of fibrinolysis. Furthermore, D-dimer concentration was significantly correlated to the level . Phase contrast microscopy shows collagen fibers adhered into the channel with a typical ball-like heap inside the dotted circle. Below, TF detected by a PE (phycoerythrin)-labeled anti-CD142 antibody (green) on the same field (magnification ×20, scale bar=20 µm). The first perfusion step forms thrombi rich in 3,3′-dihexyloxacarbocyanine iodide (DioC 6 )-labeled platelets (green) and Alexa-647 fibrin(ogen) (red). In the second perfusion step, thrombi are submitted to fibrinolysis by r-tPA (recombinant tissue-type plasminogen activator), and fluorescence was continuously recorded to assess the behavior of fibrin(ogen), platelets from the preformed thrombus and new rhodamine 6G-labeled platelets (purple). GFP indicates green fluorescent protein.
of fibrinolysis assessed by fluorescence microscopy at 1500/s and 400/s ( Figure IIA in the online-only Data Supplement).
Together, these observations indicated that the perfusion of recalcified whole blood over TF and collagen-coated surfaces allowed the formation of platelet-and FRT, suitable for the analysis of fibrinolysis in flow conditions.
Platelets Are Recruited at the Site of Ongoing Fibrinolysis
To analyze the recruitment of platelets during r-tPA-induced fibrinolysis, citrated blood was supplemented with rhodamine 6G and perfused at high or shear rate ( Figure 5A ). In the absence of r-tPA, new platelets were rapidly recruited to the preformed thrombus and contribute to its growth which eventually led to blood flow reduction or occlusion of the channel ( Figure 5A , Movie II in the online-only Data Supplement). Surprisingly, we observed that platelets continuously accumulated at the site of r-tPA-induced fibrinolysis at 1500/s and 400/s ( Figure 5A through 5C). Nevertheless, in the presence of r-tPA, the recruitment of new platelets to the preformed clot was less important than in the saline condition only at 1500/s (Figure 5B Recalcified citrated blood supplemented with 3,3′-dihexyloxacarbocyanine iodide (10 µmol/L), Alexa-647-fibrinogen (100 µg/ml), and the thrombin/Xa substrate (Z-Gly-Gly-Arg-AMC) was perfused for 4 min at 1500/s over immobilized collagen and tissue factor (TF; 1/20). A, Representative images of thrombin/Xa activity (blue), platelets (green), and fibrin(ogen) (red). B, Representative images of the accumulation of Alexa488-labeled fibrin(ogen) (green) and Alexa 647-labeled antibody against fibrin (red) during thrombus formation (left) or at the end of blood perfusion (right). C, Confocal analysis of a thrombus formed after the perfusion of whole blood on collagen and TF-coated flow chamber at the arterial shear rate. On the left, confocal images (×40) obtained at 3 different heights of the thrombus. On the right, 3-dimensional isosurface reconstruction of the thrombus with platelets labeled in green and fibrin(ogen) in red.
Effect of Anticoagulant Agents on r-tPA-Induced Fibrinolysis
Previous studies have reported that anticoagulant drugs can modulate fibrinolysis. 22 To test this claim in our model, blood was supplemented with a direct thrombin inhibitor, hirudin (20 U/mL) or with heparin (0.5 U/mL) in addition to r-tPA. We first confirmed that these inhibitors impaired thrombin generation at the indicated concentrations ( Figure IIIA in the online-only Data Supplement). We observed that hirudin accelerated fibrinolysis with a half maximum lysis reached in 3.7±0.2 minutes as compared with 4.6±0.04 minutes for r-tPA alone. In contrast, heparin (0.5 U/mL) had no effect on the rate or extent of fibrinolysis ( Figure 6A and 6B) . We also analyzed platelet recruitment during fibrinolysis in the presence of hirudin or heparin. Platelet recruitment was slightly decreased by hirudin at later times, but these differences did not reach statistical significance ( Figure 6C ). In the presence of heparin, platelet recruitment to thrombi undergoing r-tPA-triggered lysis was increased with no statistical difference ( Figure 6D ).
Effect of Antiplatelet Agents on r-tPA-Induced Fibrinolysis
To address the role of platelets in r-tPA fibrinolysis, we targeted either the main platelet integrin, αIIbβ3 with abciximab (3 µg/mL) or the ADP receptor, P2Y12, with ticagrelor (50 µmol/L), or the collagen receptor, GPVI, with the GPVI blocking Fab 9O12 (50 µg/mL). We first verified that the indicated concentration of these inhibitors effectively inhibited platelet aggregation ( Figure IIIB in the onlineonly Data Supplement). We observed that abciximab and ticagrelor did not significantly modify the rate or extent of r-tPA-induced fibrinolysis ( Figure 7A and 7B) . In contrast, the addition of the GPVI blocking Fab 9O12 (50 µg/mL) accelerated the rate of fibrinolysis with half maximum lysis reached in 3.1±0.4 minutes as compared with 4.6±0.04 minutes for r-tPA alone ( Figure 7C ). Although abciximab had no significant effect on the accumulation of new platelets at the site of ongoing fibrinolysis ( Figure 7D ), both ticagrelor and the Fab 9O12 significantly impaired the recruitment of new platelets at the site of r-tPA-mediated thrombolysis ( Figure 7E and 7F ).
Discussion
Knowledge of the mechanisms regulating fibrinolysis in whole blood under flow conditions is necessary to evaluate the potency of thrombolytic therapies. Over the past 20 years, recanalization by r-tPA has been the only recommended treatment of ischemic stroke. A major limitation of this treatment is the short therapeutic window of <4 hours after the onset of symptoms, otherwise the patient is at an increased risk of intracerebral hemorrhage. Recently, mechanical thrombectomy combined with r-tPA as a treatment in proximal large vessel occlusions have proven to achieve a better rate of complete recanalization and improved clinical outcomes. 23 However, some patients are not eligible for medical and interventional recanalization, and complete recanalization is not systematically associated to clinical improvement. Platelets are strongly suspected to play a role in the failure for thrombolysis/thrombectomy. In contrast to what has been observed in interventional cardiology, antiplatelet agents (P2Y12 antagonists, aspirin, or abciximab) are not recommended at the acute phase of ischemic stroke because of unacceptable bleeding complications in humans and animals. 24 Hemorrhagic risk also precludes the association of anticoagulant drugs with r-tPA. In this study, we used a model that mimics the therapeutic situation by first allowing the formation of fibrin-and platelet-rich thrombi at an arterial shear rate and then subjecting those preformed thrombi to lysis in a second step. The time course, the pattern of platelet adhesion and of fibrin formation observed in the first perfusion step is consistent with previously published studies. 25 With respect to fibrinolysis, our model differs from the one recently described by Whyte et al. 26 A major difference with our model system resides in the timing of plasminogen activator (r-tPA or urokinase) addition. In the study by Whyte et al, 26 r-tPA or urokinase was directly incorporated into the growing thrombus. In contrast, we perfused r-tPA after a thrombus had been formed. In addition, we monitored thrombolysis during perfusion of recalcified citrated whole blood while Whyte et al 26 used a blood cell-free buffer or heparinized blood as a thrombolysis perfusate. Nevertheless, the many characteristics of the FRT formed in flow conditions on the collagen-and TF-coated surface are concordant in both studies, such as the pattern of fibrin and platelet accumulation, as well as the incorporation of plasminogen into the fibrin network. Consistent with other reports, 27 our study shows that the binding of tPA was higher on FRT, however, we also observed that tPA can still bind to fibrin-poor clots although to a lesser degree. Our findings are in line with other studies on the ability of tPA to bind to fibrinogen 28 and platelets. 26, [29] [30] [31] In addition, our studies provide evidence that clots formed at a low wall shear rate are more susceptible to fibrinolysis than those formed at a high shear rate. These results are in contrast with those of a previous study by Wootton et al 32 who showed that fibrinolysis was enhanced at arterial flowrate as compared with venous flowrate, a result that was also reported by Graham et al. 33 Several notable differences between our experimental design and that of those previous studies can explain these apparent discrepancies: (1) both Wootton et al 32 and Graham et al 33 studied fibrinolysis in a model of nonocclusive mural thrombus versus nonocclusive intraluminal thrombus in our study, (2) whereas we studied fibrinolysis of clots formed in flowing citrated whole blood, Wooten et al 32 studied purified fibrinogen treated with thrombin and Graham et al 33 noncross-linked fibrin, and (3) we studied the effect of r-tPA in whole blood, Wooten et al 32 studied it in platelet-poor plasma. Notably, Nishino et al 34 showed opposite effects of flow velocity on the rate of fibrinolysis depending on the type of thrombi (fibrin thrombi versus whole blood thrombi). Thus, considering our results with those of previous studies, including that of Wooten et al, 32 one can conclude that the rate of tPA-mediated fibrinolysis is not solely dependent on blood flow rate but also on other parameters, such as clot composition (eg, pure fibrin versus blood clot), location (eg, intraluminal versus mural), and occlusive status.
To enable a consistent visualization of fibrinolysis within the restricted time window of 10 minutes, we infused r-tPA at a concentration of 15 µg/mL (0.2 µmol/L). This tPA concentration is higher than the plasma concentration obtained on infusion of alteplase to healthy volunteers or patients: pharmacokinetic studies indicated alteplase concentrations reached steady levels of 1.83 µg/mL for an infusion of 0.5 mg/kg body weight >30 minutes, while in acute myocardial infarction patients the administration of alteplase as a 10 mg bolus followed by continuous infusion of 50 mg >1 hour achieved peak and steadystate concentrations of 3.31±0.95 and 2.21±0.47 µg/mL. 35 Nevertheless, in a previous study by Graham et al, 33 tPA doses of 0.1, 1, and 10 µg/mL in non-recalcified blood were compared for their fibrinolytic activity against noncross-linked fibrin surfaces under static and arterial flow conditions. One can see that in for all tPA concentrations tested, the effect of tPA becomes visible only after 20 minutes of perfusion, thus arguing for the use of higher doses to ensure rates of fibrinolysis that would be measurable during the reperfusion experiment time window. We, however, do not exclude the possibility of using lower r-tPA doses although this may lead to a greater variability in results.
An important novelty in our work is to have examined the behavior of circulating platelets during blood perfusion over preformed FRT undergoing r-tPA-mediated fibrinolysis. As expected, new platelets were found to accumulate on these thrombi in the absence of any drugs. The accretion of new platelets was so important that it resulted in flow reduction and sometimes in occlusion of the channel. But, unexpectedly, we also observed that platelets continued to accumulate at the sites where FRT were undergoing efficient fibrinolysis during perfusion of r-tPA-containing blood. This accumulation of new platelets was significantly reduced only at a high shear rate as compared with control conditions (in the absence of r-tPA) and resulted in the transformation of a fibrin-rich thrombus into a smaller platelet-rich one. However, under low shear, we observed that tPA did not modify platelet accumulation at sites of undergoing fibrinolysis. This difference is consistent with a previous report where it was shown that fibrinolytic enzymes can cause fibrinogen degradation products which can impair αIIbβ3 binding to insoluble VWF at high shear and lead to decreased platelet adhesion. 36 Such an accumulation of platelets at the site of ongoing fibrinolysis could be regarded as a cause of thrombolysis failure, being responsible for an incomplete restoration of the blood flow and also because activated platelets are an important source of the fibrinolysis inhibitors, PAI-1 (plasminogen activator inhibitor-1), and PN-1 (protease nexin-1), 37, 38 as well as polyphosphates, which impair the assembly of the ternary plasminogen/tPA/fibrin complex. 39 Interestingly, this process has never been reported in other in vitro assays developed to analyze fibrinolytic agents, which were in static conditions (clot lysis assays and thromboelastography). 40 We examined the effect of different pharmacological agents on the time course of fibrinolysis and observed that hirudin accelerated r-tPA-triggered fibrinolysis. This is in line with a Figure 7 . Effect of combined antiplatelet agents and r-tPA (recombinant tissue-type plasminogen activator) on fibrinolysis and platelets in flow conditions. Citrated blood supplemented with rhodamine 6G (100 µmol/L), r-tPA (15 µg/mL) and with platelet inhibitor targeting αIIbβ3 integrin (abciximab 3 µg/mL) or P2Y12 (purinoreceptor 12) receptor (ticagrelor 50 µmol/L) or GPVI (glycoprotein VI) antagonist (Fab 9O12 50 µg/mL) or vehicle (Ctl), was perfused for 10 min at 1500/s into the channel containing preformed thrombi. A through C, The extent of fibrinolysis and (D through F) platelet accumulation were quantified during the time frame. Data are the mean±SEM, n=4 to 6, **P<0.01 and *P<0.05.
previous report showing that hirudin enhanced fibrinolysis in an in vivo model. 41 Because of its extremely high affinity for thrombin and its low-molecular-weight, hirudin is a good inhibitor of fibrin-bound thrombin and it could also block thrombin potentially formed when citrated blood is perfused over preformed clots. 42 Nevertheless, the weak effect of hirudin on the recruitment and, therefore, the activation of platelets in the second step argues against the neoformation of thrombin in the second step. Mechanisms other than activation of the thrombin receptors, PARs (protease-activated receptors), are thus likely to be responsible for platelet accretion at the site of ongoing fibrinolysis.
Heparin at the dose of 0.5 U/mL had no effect on fibrinolysis. Because AT (antithrombin) is unable to inhibit fibrin-bound thrombin even in the presence of heparin, in contrast to hirudin, 43 this observation further supports a role for fibrin-bound thrombin in the regulation of fibrinolysis. The paradoxical trend towards an increased platelet accumulation at the site of ongoing fibrinolysis in the presence of heparin did not reach statistical significance, and further experiments would be required to confirm and explain this effect that is out of the scope of the present study.
About antiplatelet agents, abciximab at a dose that efficiently prevent platelet aggregation had only a small, nonsignificant reducing effect on the accumulation of new platelets and only at later times. This suggests that platelet accretion at the site of ongoing fibrinolysis involves a mechanism other than the binding of integrin αIIbβ3 to remnant fibrin or fibrin degradation products. Furthermore, platelet-platelet interactions in the newly formed platelet thrombus may also be mediated in the present conditions by interactions other than integrin-bound fibrinogen, at least in the first few minutes. Whether newly recruited platelets are weakly activated, as described for platelets forming the shell of a growing thrombus 44 requires further investigation to determine. In contrast, ticagrelor consistently reduced the growth of the newly formed platelet thrombus at the site of ongoing fibrinolysis, suggesting that ADP and its receptor P2Y12 play a critical role in platelet recruitment. However, the rate of fibrinolysis was not affected by combining ticagrelor and r-tPA as compared with r-tPA alone. We additionally tested the effect of the GPVI blocking Fab 9O12 in our model of thrombolysis and observed that the formation of the newly formed platelet thrombus at the site of ongoing fibrinolysis was significantly inhibited in agreement with the fact that GPVI has recently been recognized as a receptor for fibrin 45, 46 with the fibrin D-dimer bearing the GPVI binding site. 47 Additionally, a slight but significant acceleration of fibrinolysis was observed suggesting that platelets recruited via GPVI exert an antifibrinolytic effect.
The model of fibrinolysis described here represents a good preclinical assay to assess fibrinolysis with the major advantage of providing information on the behavior of platelets at the site of ongoing fibrinolysis. It is certainly improvable and could be adapted to multiple specific situations that could not be systematically analyzed in this study. For example, the nature of the proteins coating the flow chamber could be modified with the use of matrix proteins other than type I collagen or extracts from atherosclerotic plaques and the use of various TF concentrations. Another limit is the structure of the primary thrombus: here stable thrombi were observed after the first 3 to 4 minutes of flow followed by a 1-minute washing at 1500/s or 400/s. However, these fresh thrombi are probably more susceptible to lysis by r-tPA than aged thrombi. The nature of the anticoagulant used may also be of importance because it may be expected that anticoagulation with hirudin in the second step favors fibrinolysis.
In conclusion, we describe a microfluidic model that is suitable for comparative evaluation of thrombolytic therapies in human whole blood under flow conditions. This model can be used to deepen the understanding of the mechanisms that limit thrombolysis and provides a basis that can be adapted to address the many questions still unanswered.
